Deals, Insiders, Venture

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,700+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->